Clinical trial

Korean Post-marketing Surveillance for Xeljanz XR

NCT04876781

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2022-01-12

PhaseN/A

Study timeline

Study start (actual)2022-01-12Date precision: day

Registry last updated2026-08-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Active Moderate to Severe Rheumatoid Arthritisunresolved

Active Ankylosing Spondylitisunresolved

Active Psoriatic Arthritisunresolved

Interventions

Tofacitinib XRDRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04876781 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.